Presbia PLC

Presbia — Jefferies Healthcare Conference 2015

26 slides from Presbia's conference presentation, Jun 3, 2015

  1. Slide 1: Jefferies Healthcare Conference, New York, June 2015

    Slide 1: Jefferies Healthcare Conference, New York, June 2015

    Exhibit 99.1 Jefferies Healthcare Conference New York June 2015

  2. Slide 2: Disclosure

    Slide 2: Disclosure

    Disclosure To the extentstatementscontainedin this presentationarenot descriptionsof historicalfactsregardingPresbiaPLCandits subsidiaries(collectively “Presbia,”“we,” “us,” or “our”), they areforward-lookingstatementsreflectingmanagement’scurrentbeliefsandexpectations.Forward-looking statementsares

  3. Slide 3: Key Contributors

    Slide 3: Key Contributors

    Key Contributors Name Title Previous Experience • Named Executive Chairman in January 2014 • Director since October 2013 • Held President and CEO positions in the medical device and pharmaceutical industries Randy for 25 years Executive Chairman Thurman – VIASYS Healthcare Inc., Founder, Chairman an

  4. Slide 4: Business Highlights

    Slide 4: Business Highlights

    Business Highlights Large, Underserved • 113 million presbyopes in the U.S.; 1.8 billion presbyopes worldwide (2013) Presbyopia Opportunity • Over 4,000 ophthalmic surgery centers with no effective treatment of presbyopia Developed Ophthalmic • Ophthalmic surgeons are highly motivated to develop thi

  5. Slide 5: Presbyopia

    Slide 5: Presbyopia

    Presbyopia A Loss of Near Vision Affecting the Majority of People over the Age of 40 • Clinical Advantages of the Presbia MicroLens – Presbia MicroLens is tailorable to a patient’s specific, desired near visual acuity reading distance – Crystal clear material that is not visible to the naked eye – O

  6. Slide 6: Large, Underserved Presbyopia Opportunity

    Slide 6: Large, Underserved Presbyopia Opportunity

    Large, Underserved Presbyopia Opportunity 1.8 Billion Presbyopes in Targeted Markets Demographic-Driven Market Growth (millions) (billions) United States (113) Western Europe (165) Rest of World Japan (542) (58) Other Wealthy Nations (71) Latin America (140) India (249) China (423) Source: 2013 Mark

  7. Slide 7: No Capital Investment Required

    Slide 7: No Capital Investment Required

    No Capital Investment Required MicrolensTM Procedure Uses Existing, Underutilized Femtosecond Laser Equipment Existing Femtosecond Laser Excess Capacity in U.S. LASIK Market (millions) Source: 2013 Market Scope. CONFIDENTIAL | 6 |

  8. Slide 8: Clearly Differentiated Microlens Technology

    Slide 8: Clearly Differentiated Microlens Technology

    Clearly Differentiated Microlens Technology

  9. Slide 9: Microlens Surgical Procedure

    Slide 9: Microlens Surgical Procedure

    Microlens Surgical Procedure 10 Minute Procedure Utilizing Existing Femtosecond Laser 1 Femtosecond Laser Creates a pocket in patient’s cornea 2 Proprietary Inserter Surgeon uses inserter to implant lens in patient’s cornea Proprietary Insertion Tool 3 Self-Sealing Pocket Pocket self-seals, holding

  10. Slide 10: Mechanism of Action

    Slide 10: Mechanism of Action

    Mechanism of Action NEAR VISION with Presbia Flexivue Microlens™ Peripheral portion of microlens helps focus light from near objects (blue light rays) onto retina FAR VISION with Presbia Flexivue Microlens™ Central portion of microlens allows light from far objects to enter eye and focus clearly (ye

  11. Slide 11: Presbia Microlens Technology

    Slide 11: Presbia Microlens Technology

    Presbia Microlens Technology Actual Size 3.2 mm Overall Diameter Presbia Flexivue Microlens™ Designed to Eliminate Need for Reading Glasses • IntracornealRefractiveLensimplantedin a pocketin corneaof non-dominanteye 0.51 mm Central Hole Diameter • HydrophilicAcrylicMaterialsimilarto that used 1.6 mm

  12. Slide 12: Presbia's Microlens Clinical Results

    Slide 12: Presbia's Microlens Clinical Results

    Presbia’s Microlens Clinical Results Average 6 Lines of Improvement in Near-Vision Average Preop UCVA-near Starting Point = 20/110 Average Postop UCVA-near Ending Point = 20/27 Source: Presbia post-market surveillance study (CPL-10-002). CONFIDENTIAL | 11 |

  13. Slide 13: OUS 12-Month Multicenter Trial

    Slide 13: OUS 12-Month Multicenter Trial

    OUS 12-Month Multicenter Trial Positive Clinical Results of 12-Month Multicenter Uncorrected Near Visual Acuity Operated Eye Uncorrected Binocular Distance Visual Acuity (33 cm chart) (N=70 at Month 12) (N=70 at Month 12) Average of 6 lines gained Binocular UCVA-distance remained in UCVA-near by Mon

  14. Slide 14: U.S. Pivotal Trial

    Slide 14: U.S. Pivotal Trial

    U.S. Pivotal Trial U.S. Staged Pivotal Clinical Trial Timeline • January 2015: Submitted interim safety report to FDA, which included 6-month data on 52 subjects (a total of 75 subjects were implanted at six investigational sites in the first stage of this trial) • February 2015: – Approved to begin

  15. Slide 15: Clear U.S. Regulatory Pathway

    Slide 15: Clear U.S. Regulatory Pathway

    Clear U.S. Regulatory Pathway TargetedU.S.IDERegulatoryPathway– PresbiaFlexivueMicrolens™ Q2 2014: Q3 2014: Q2 2015: Q1 2015: Q4 2017: Q2 2018: Commencement of 75 th patient treated Continuance of Receive PMA Submit final report pivotal trial (75 (6 sites) enrollment in U.S. approval (36 month data)

  16. Slide 16: Clearly Differentiated Microlens Technology

    Slide 16: Clearly Differentiated Microlens Technology

    Clearly Differentiated Microlens Technology AcuFocus KAMRA ReVision Optics Raindrop Intracorneal Refractive Lens; Creates a Pinhole Effect; Adds Bulk to Cornea; Implanted in a Pocket Implanted in a Pocket Implanted under a LASIK-like Flap Wide Range of Refractive Powers X X Aesthetically Appealing X

  17. Slide 17: Intellectual Property

    Slide 17: Intellectual Property

    Intellectual Property U.S. Patents • Three patents issued: • Five patents pending (patent applications): – Lens Holder Apparatus and System Method – Lens Injector Apparatus and Method – Lens Inserter Apparatus and Method – Method for Laser Cutting a Corneal Pocket – Lens Injector Apparatus System an

  18. Slide 18: New Product Pipeline

    Slide 18: New Product Pipeline

    New Product Pipeline New Microlens Delivery Systems 1 Disposable 2 Preloaded and Disposable Estimated approval in Q3 2016; Estimated approval in Q3 2015; 510(k) PMA submission required Molded Disposable Inserter: Molded Preloaded Disposable Inserter: • Lens insertion technique and inserter design •

  19. Slide 19: Strong Leadership and Compelling Business Model

    Slide 19: Strong Leadership and Compelling Business Model

    Strong Leadership and Compelling Business Model

  20. Slide 20: Presbyopia Surgery is the Missing Piece in Refractive Surgery

    Slide 20: Presbyopia Surgery is the Missing Piece in Refractive Surgery

    Presbyopia Surgery is the Missing Piece in Refractive Surgery Currently There is No Established Surgical Market for the 40–60 Year Old Patient Pool Presbyopia LASIK Cataract Patient Age 20 30 40 50 60 70 80 Refractive Surgery Centers PresbiaFlexivueMicrolens™ Procedure • Hit hard by flat-to-declinin

  21. Slide 21: Presbia Sales Process

    Slide 21: Presbia Sales Process

    Presbia Sales Process Presbia-Sponsored Direct Response Marketing • Presbiacreates awareness through direct response media campaign (digital, print, television, radio) • Prospective patients contact Presbia call center • Presbiascreens patients and directs inquiries to clinic • Presbiastreamlinespat

  22. Slide 22: The Patient Funnel: U.S. Clinical Trial Example

    Slide 22: The Patient Funnel: U.S. Clinical Trial Example

    The Patient Funnel U – .S. Clinical Trial Example: Stage 1 Create Patient Awareness through DTC Advertising ($80,000 Expenditure for Advertising and Call Center during Trial) 1,166 Calls ($68 per Lead) 487 Qualified ($163 per Qualified Lead) Conversion of Patients 679 Disqualified by CC & Clinic is

  23. Slide 23: OUS Commercialization

    Slide 23: OUS Commercialization

    OUS Commercialization Proven Commercialization Strategy, Creating Patient Awareness Generating Revenues • Focus on surgicalcenters in selected region • Regional teams – Presbia educates and trains surgeons on – Business Development Microlens procedure – Clinical Services Team – Presbia-funded direct

  24. Slide 24: Manufacturing

    Slide 24: Manufacturing

    Manufacturing Irvine, CA Manufacturing Facility • Completed construction of 4,000 square-foot, two-part (wet/dry) manufacturing facility in Q3 2013 • Approved to manufacture devices for U.S. IDE by State of California FDA in 2013 • Sufficientcapacityto handleprojectedMicrolensvolumethrough U.S.launc

  25. Slide 25: Experienced Leadership Team

    Slide 25: Experienced Leadership Team

    Experienced Leadership Team Randy Thurman Executive Chairman Todd Cooper President,ChiefExecutiveOfficer& Director Vlad Feingold Chief Technology Officer & Director Richard Fogarty Chief Accounting Officer & VP Finance John Strobel Vice President of Sales Vanessa Tasso Vice President of Clinical Aff

  26. Slide 26: Business Highlights

    Slide 26: Business Highlights

    Business Highlights Large, Underserved • 113 million presbyopes in the U.S.; 1.8 billion presbyopes worldwide (2013) Presbyopia Opportunity • Over 4,000 ophthalmic surgery centers with no effective treatment of presbyopia Developed Ophthalmic • Ophthalmic surgeons are highly motivated to develop thi

Source: SEC EDGAR · 8-K filed Jun 3, 2015

More decks from Presbia PLC